![]() ![]() The prognostic performance of the score cut-off persisted beyond the first year after AMI in the validation cohort, maintaining a similar risk for death and non-fatal AMI (HR 3) at every following year. One-year major bleeding rate was low (<0.2% overall) and similar between risk groups. LONDON (dpa-AFX) - AstraZeneca (AZN, AZN. Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. At multivariate analysis, the HR for the primary endpoint associated with a score ≥ 6 was 4.45 (P < 0.0001) in the derivation cohort and 2.86 (P < 0.0001) in the validation cohort. The primary endpoint incidence in patients with a score above and below the cut-off was 12% and 3% (P < 0.001) in the derivation cohort and 16% and 6% in the validation cohort (P < 0.001). In the derivation cohort, the area under the curve of the score for the primary endpoint (1-year death and non-fatal AMI) was 0.70 (95% CI 0.65-0.76 P < 0.0001) and a cut-off of 6 was identified. We externally validated our score in 913 AMI patients with a longer follow-up. We calculated a cut-off for the developed score and investigated its 1-year prognostic power in the derivation cohort (n = 1257). We retrospectively analyzed two prospectively collected AMI cohorts. Tab.1 Haupt-undNebenkriterienfürhohesBlutungsrisikonachdemAcademicResearchCon- sortiumHighBleedingRisk(ARC-HBR)zumZeitpunktderperkutanenKoronarintervention.Das. We aimed to elaborate a risk score, based on the PEGASUS-TIMI 54 criteria, to predict mortality and non-fatal AMI in AMI patients. PEGASUSTIMI 54: Ticagrelor linked with better outcomes in patients at least 1 year after MI SAN DIEGO - Treatment with ticagrelor reduced the risk for CV death, MI or stroke in patients with. The marketing authorisation for ticagrelor as an extended therapy was based on prespecified subgroup analyses. In die PEGASUS-TIMI-54-Studie (Bonaca MP et al. PEGASUS TIMI 54 TRIALAcute myocardial infarction (AMI) patients are at increased risk of death and recurrent ischemic events. 4.6 The company presented clinical effectiveness results for the PEGASUSTIMI 54 trial whole population who had ticagrelor compared with placebo (ticagrelor n7,045, placebo n7,067). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |